C12N 2740/16044
Chimeric viral vector comprising heterologous viral elements for production of another viral
Official title: Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2740/16044 (Chimeric viral vector comprising heterologous viral elements for production of another viral) appears on 12 US grants and 24 published applications in this corpus.
Search patents in C12N- Granted patents
- 12
- Published applications
- 24
- Assignees
- 14
- Inventors
- 52
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 2 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 4 |
| 2020 | 0 | 2 |
| 2021 | 1 | 1 |
| 2022 | 1 | 3 |
| 2023 | 0 | 1 |
| 2024 | 2 | 3 |
| 2025 | 2 | 3 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- Modified HIV-1 proviral vectors with enhanced dendritic cell transduction efficiencies comprising the JRFL envelope23 Dec 2025US 12,503,499 B2University of Massachusetts
- Mammalian cells and methods for engineering the same4 Mar 2025US 12,241,062 B264-X, Inc.
- Non-integrating viral delivery system and methods related thereto7 May 2024US 11,976,292 B2American Gene Technologies International Inc.
- Compositions and methods for treating age-related diseases6 Feb 2024US 11,891,442 B2The Board of Trustees of the Leland Stanford Junior University
- Engineered protein g fusogens and related lipid particles and methods thereof13 Aug 2026US 2026/0234669 A1Sana Biotechnology, Inc.
- Use of modified hiv-1 for generating fully human antibodies2 Jul 2026US 2026/0184767 A1University of Massachusetts
- Non-integrating viral delivery system and methods related thereto5 Jun 2025US 2025/0179150 A1American Gene Technologies International Inc.
- Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production3 Apr 2025US 2025/0109411 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Non-integrating viral delivery system and methods related thereto6 Feb 2025US 2025/0042975 A1American Gene Technologies International Inc.
Most cited
By later US patents
- Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production12US 10,174,341 B2University of Pittsburgh—Of the Commonwealth System of Higher Education · 2019
- Composition of trans-dominant variants of viral proteins for obtaining an anti-viral effect4US 6,228,369 B1Transgene S. A. · 2001
- Generation of human anti-HIV-1 ENV monoclonal antibodies with neutralizing activity from humanized mice infected with HIV-11US 11,142,566 B2University of Massachusetts · 2021
- Composition and method for inhibiting amyloid β accumulation and/or aggregation1US 11,498,957 B2Innopeutics Corporation · 2022
- Non-integrating viral delivery system and methods related thereto1US 11,976,292 B2American Gene Technologies International Inc. · 2024